MDNA Life Sciences Inc. (MDNA), the molecular diagnostics company revolutionizing the development of liquid biopsy biomarkers based on the mitochondrial genome, announced today the that the Mitomic® Prostate Test (MPT™) is ready for release in the UK.
MDNA Life Sciences has entered into an exclusive license agreement with LabCorp® (LH) to develop and commercialize a non-invasive test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA “grey zone”.
Phi is our first US partner to distribute our proprietary liquid biopsy test for prostate cancer, the Mitomic Prostate Test (PMT™).
Specimen Testing is Now Commercially Available in the Clinical Laboratories of Helomics Corporation.